Key result
After almost 3 years of follow-up, 79% of patients with atrial fibrillation and breast cancer remained on oral anticoagulation, compared to 87% of patients without cancer.
Answers are grounded in this paper and cite their sources.
This commentary highlights that oral anticoagulation prescription and persistence rates in patients with AF and breast cancer are encouragingly high, contrary to general concerns of underuse.
Results of the AMBER-AF registry were recently reported [[1]Pardo Sanz A. Rincón L.M. Guedes Ramallo P. Belarte Tornero L.C. de Lara Delgado G. Tamayo Obregon A. et al.Current status of anticoagulation in patients with breast cancer and atrial fibrillation.Breast. 2019; 46: 163-169Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar]. The authors find that 80% of patients with atrial fibrillation (AF) and breast cancer and 85% without cancer were prescribed oral anticoagulation (OA) at study outset and about 79% and 87%, respectively, after completion of follow-up [[1]Pardo Sanz A. Rincón L.M. Guedes Ramallo P. Belarte Tornero L.C. de Lara Delgado G. Tamayo Obregon A. et al.Current status of anticoagulation in patients with breast cancer and atrial fibrillation.Breast. 2019; 46: 163-169Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar]. The authors emphasize that anticoagulation is underused in patients with AF and breast cancer but we find this to be a half-empty take on an otherwise quite full glass. Anticoagulation underuse in AF is a well-reported concern, with anticoagulation rates<70% in the general population [[2]Lip G.Y.H. Rushton-Smith S.K. Goldhaber S.Z. Fitzmaurice D.A. Mantovani L.G. Goto S. et al.Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.Circ Cardiovasc Qual Outcomes. 2015; 8: S12-S20Crossref PubMed Scopus (71) Google Scholar,[3]Chapman S.A. St Hill C.A. Little M.M. Swanoski M.T. Scheiner S.R. Ware K.B. et al.Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation.BMC Health Serv Res. 2017; 17: 127Crossref PubMed Scopus (11) Google Scholar]. Similarly, after almost 3 years, 79% of patients with cancer remained under OA(1% drop) [[1]Pardo Sanz A. Rincón L.M. Guedes Ramallo P. Belarte Tornero L.C. de Lara Delgado G. Tamayo Obregon A. et al.Current status of anticoagulation in patients with breast cancer and atrial fibrillation.Breast. 2019; 46: 163-169Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar]. Steep discontinuation rates are a constant finding in studies in the general population [4Björck F. Ek A. Johansson L. Själander A. Warfarin persistence among atrial fibrillation patients - why is treatment ended?.Cardiovasc Ther. 2016; 34: 468-474Crossref PubMed Scopus (6) Google Scholar, 5Raparelli V. Proietti M. Cangemi R. Lip G.Y.H. Lane D.A. Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants.Thromb Haemost. 2017; 117: 209-218Crossref PubMed Scopus (147) Google Scholar, 6Brown J.D. Shewale A.R. Talbert J.C. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation.J Manag Care Spec Pharm. 2016; 22: 1319-1329Crossref PubMed Scopus (55) Google Scholar, 7Gopalakrishnan C. Schneeweiss S. Bartels D.B. Zint K. Santiago Ortiz A. Huybrechts K.F. Evaluating utilization patterns of oral anticoagulants in routine care.J Thromb Haemost. 2019; 17: 14467Google Scholar]. Of course, patients treated in a registry in tertiary healthcare institutions may receive more evidence-based treatment than other subgroups but the AMBER-AF results are positive and a solid foundation for randomized trials to optimize management of AF in patients with cancer/breast cancer. To conclude, we understand the investigators’ disappointment over use of anticoagulation [[1]Pardo Sanz A. Rincón L.M. Guedes Ramallo P. Belarte Tornero L.C. de Lara Delgado G. Tamayo Obregon A. et al.Current status of anticoagulation in patients with breast cancer and atrial fibrillation.Breast. 2019; 46: 163-169Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar] and we share their concern over the higher stroke rates in patients with breast cancer. However, the authors should be commended both for their effort and their achievements on evidence-based care. None. None.
No takes yet. Share an insight, caveat, or question.
Marc Sorigué (2019) conducted a letter in Atrial fibrillation and breast cancer. Oral anticoagulation vs. Patients without cancer was evaluated on Oral anticoagulation prescription after completion of follow-up. After almost 3 years of follow-up, 79% of patients with atrial fibrillation and breast cancer remained on oral anticoagulation, compared to 87% of patients without cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: